Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM-023 in Pachyonychia Congenita
NCT07893483Phase 2Not yet recruiting
- Sponsor
- Orvida Pharma
- Start
- Dec 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ainuovirine in pachyonychia congenita (PC), sponsored by Orvida Pharma. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ainuovirine
03
Conditions
pachyonychia congenita (PC)
Beyond the preview
Go deeper on NCT07893483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893483.